1-3 of 3
Maria Debiec-Rychter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ponatinib Is Active Against the CUX1-FGFR1 Fusion Kinase and Against Imatinib Resistance Mutations of the FIP1L1-PDGFRα Fusion Kinase and of KIT,

Els Lierman, PhD, Sanne Smits, Jan Cools, PhD, Barbara Dewaele, PhD, Maria Debiec-Rychter, MD PhD, Peter Vandenberghe, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3848.
https://doi.org/10.1182/blood.V118.21.3848.3848
Published: 2011
Journal Articles

Activity of Dasatinib Against Novel KIT-N822I Mutation In Familial Cutaneous Mastocytosis

Bartosz Wasag, PhD, Marek Niedoszytko, MD, PhD, Anna Piskorz, PhD, Magdalena Lange, MD, PhD, Joanna Renke, MD, PhD, Ewa Jassem, MD, PhD, Maria Debiec-Rychter, MD, PhD, Janusz Limon, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 4088.
https://doi.org/10.1182/blood.V116.21.4088.4088
Published: 2010
Journal Articles

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants

Ellen Weisberg, Hwan Geun Choi, Arghya Ray, Rosemary Barrett, Jianming Zhang, Taebo Sim, Wenjun Zhou, Markus Seeliger, Michael Cameron, Mohammed Azam, Jonathan A. Fletcher, Maria Debiec-Rychter, Mark Mayeda, Daisy Moreno, Andrew L. Kung, Pasi Antero Janne, Roya Khosravi-Far, Junia V. Melo, Paul W. Manley, Sophia Adamia, Catherine Wu, Nathanael Gray, James D. Griffin
Journal: Blood
Blood (2010) 115 (21): 4206–4216.
https://doi.org/10.1182/blood-2009-11-251751
Published: 2010
Includes: Supplemental data